Ondansetron Fresenius Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetron Fresenius Kabi, is a 5-HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It helps prevent nausea and vomiting caused by chemotherapy, radiotherapy, and postoperative recovery in adult and pediatric patients.

GNH USA supplies Ondansetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Ondansetron Fresenius Kabi is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting associated with several clinical pathways. - Chemotherapy‑induced nausea and vomiting: Reduces the frequency and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: Helps control nausea during and after radiation treatment. - Post‑operative nausea and vomiting: Decreases the incidence of vomiting after surgical procedures. - Pregnancy‑related hyperemesis gravidarum (off‑label): May be considered when conventional therapy fails, under specialist supervision. - Anticipatory nausea: Used in patients who develop nausea in anticipation of chemotherapy sessions.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement reduction. - Diarrhoea: transient loose stools. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests. - Vision changes: blurred vision or visual disturbances.

When using Ondansetron Fresenius Kabi, clinicians should consider several safety aspects. - Cardiac monitoring: patients with known QT prolongation or electrolyte disturbances should be observed. - Electrolyte balance: correct hypokalaemia, hypomagnesemia, or hypocalcaemia before administration. - Concomitant serotonergic drugs: assess risk of serotonin syndrome. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly indicated. - Pediatric dosing: ensure weight‑based calculations are applied accurately. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Ondansetron may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Amiodarone: increased risk of QT prolongation and arrhythmia. - Certain anti‑malarial drugs (e.g., quinidine): additive QT‑prolonging effect. - Cis‑cobalt cobalt c c  ");

Moderate "); -  "); - "); - "); - "); - ");